Healthcare · NSE: TORNTPHARM
Intrynsic's multi-model valuation estimates Torrent Pharmaceuticals Limited's fair value at ₹2,142 per share (range ₹1,251–₹2,179) against a market price of ₹4,894 - a gap of -56.2% (updated 29 September 2026). This is an estimated fair value based on stated assumptions, not investment advice.
Market price
₹4,894
close of 29 Sept 2026
Est. fair value
₹2,142
₹1,251–₹2,179
Gap
-56.2%
price vs estimate
Trading ~56% above our estimated fair-value range. Assumptions and per-model workings are below.
Torrent Pharmaceuticals makes branded generic medicines, mainly for India, Brazil and Germany, with strength in heart and diabetes drugs. Growth in its Indian branded portfolio drives most of its profit.
Healthcare · Healthcare Services
Over the last 3 years, revenue grew 13.3%/yr and profit grew 19.8%/yr.
Every ₹100 of shareholder money earned ₹25.5 in profit last year, vs a sector median of 10.6%.
Debt is 1.79x shareholder equity and 3.0x yearly operating earnings — a heavy load.
The market price is above our estimated fair-value range (based on stated assumptions).
About ₹144 of every ₹100 of reported profit turned into free cash (median, last 5 years); operating cash flow was positive in 5 of 5 years.
Intrynsic values Torrent Pharmaceuticals Limited with 3 independent models and blends them into one estimated fair-value range. Every number below is an estimate based on the stated assumptions - change the assumptions and the estimate changes.
| Model | Estimated value | vs price | Weight |
|---|---|---|---|
| DCFFuture Cash Flows Method | ₹1,251 | -74% | - |
| EV/EBITDAIndustry Comparison Method | ₹2,142 | -56% | - |
| P/E MultipleEarnings Multiple Method | ₹2,179 | -55% | - |
Reverse DCF: today's market price implies the company must grow free cash flow about 42.4% a year for the next decade - versus 13.2% historical revenue growth.
| Revenue | ₹13,980 Cr | |
| Net profit | ₹2,138 Cr | |
| EPS | ₹63.92 | |
| Free cash flow | ₹2,346 Cr | |
| ROE (latest) | 25.5% | |
| Revenue growth (CAGR) | 10.2% | |
| Profit growth (CAGR) | 9.6% |
Intrynsic's multi-model valuation estimates Torrent Pharmaceuticals Limited's fair value at ₹2,142 per share (range ₹1,251–₹2,179), last updated 29 September 2026. This is an estimate based on stated assumptions, not investment advice.
Torrent Pharmaceuticals Limited trades at ₹4,894 against Intrynsic's estimated fair value of ₹2,142 - the market price is 56% above the estimate, i.e. above our estimated fair-value range. Different assumptions produce different estimates; see the model breakdown above.
Torrent Pharmaceuticals Limited trades at about 76.6 times its latest annual earnings per share.
Torrent Pharmaceuticals makes branded generic medicines, mainly for India, Brazil and Germany, with strength in heart and diabetes drugs. Growth in its Indian branded portfolio drives most of its profit.
Intrynsic runs 3 valuation models for Torrent Pharmaceuticals Limited (DCF, EV/EBITDA, P/E Multiple) and blends them into one estimated fair-value range. Every assumption - growth, discount rate, terminal value - is shown openly on this page.
Disclaimer: Intrynsic provides educational and informational analysis only. Fair-value figures are estimates based on stated assumptions - they are not investment advice, research recommendations, or an offer to transact in any security. Intrynsic is not a SEBI-registered investment adviser or research analyst. Markets carry risk; please do your own research or consult a registered adviser before making investment decisions. Prices shown may be delayed end-of-day values. Terms · Privacy